Technology | May 11, 2012

Sorin Group Releases New Devices, Data at HRS

May 11, 2012 — The Sorin Group is launching new implantable devices with a proprietary algorithm system as well as three leads, and releasing data showing improved patient outcomes with a novel CRT (cardiac resynchronization therapy) optimization system. The company highlighted this news during the Heart Rhythm Society 2012 meeting this week in Boston.

Data Shows Improved Outcomes, Cost

In clinical testing, Sorin Group’s CLEAR study demonstrated that at one year, 76 percent of patients using Sorin Group’s SonR system to automatically optimize a patient’s heartbeat (allowing the heart to beat in a more coordinated and synchronized way) were classified as improved. Based on these data, it is possible that more heart failure patients will respond to automatic optimization CRT than with current optimization methods. This system is the only CRT optimization system that automatically optimizes a patient’s heartbeat every week and while the patient is active, which provides real-life optimization.

U.S. Launch of News Devices

HRS 2012 marks the launch of the Paradym RF family of implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy devices (CRT-D) that allow for remote monitoring and adjustment through a proprietary algorithm system, with improved electrical performances and electrical reliability. The Paradym RF products allow heart failure patients who often undergo cardiac rehabilitation, including physical exercise, to increase their heart rates while maintaining the ability to treat heart rhythm irregularities.

FDA Approval Broadens Access to U.S. Physicians

For the first time in the United States, Tilda, Vigila and Celerity leads offer a complete package for physicians to better manage their patients’ individualized needs. Tilda pacing leads are designed for easy implantation and predictable performance. Vigila defibrillation leads feature a symmetrical lead body and thick outer insulation, and are engineered to minimize tissue in-growth. Celerity left ventricular leads are designed to facilitate access and ensure stability in targeted pacing sites, regardless of patients’ coronary venous anatomies.

For more information: www.sorin.com

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init